SCYNEXIS Investor Relations Material
Latest events
Q1 2025
15 May, 2025
Q4 2024
12 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from SCYNEXIS Inc
Access all reports
SCYNEXIS Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapies for fungal infections. The company's lead product, based on a novel antifungal platform, is designed to address severe and drug-resistant fungal infections in both hospital and outpatient settings. SCYNEXIS develops treatments for conditions with significant unmet medical needs, with a particular emphasis on antifungal agents targeting life-threatening infections. The company is headquartered in Jersey City, USA, and its shares are listed on the NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
SCYX
Country
🇺🇸 United States